IMPROVE-PD

IMPROVE-PD is a European Action titled: ‘Identification and Management of Patients at Risk – Outcome and Vascular Events in Peritoneal Dialysis’.

IMPROVE PD connects leading researchers who will collaborate in the shared goal of understanding the mechanisms of inflammation-driven cardiovascular disease in Peritoneal Dialysis (PD) patients, developing individualized approaches to identify those at risk, and testing new therapies in them.

Network-wide and local training activities including academies and satellite modules associated with large nephrology conferences, combined with individual research projects, intersectoral secondments and short laboratory visits, will provide key generic skills including valorisation, entrepreneurship and intellectual property management and will prepare ESRs for future roles as highly skilled research leaders in Europe.

WHAT IS IMPROVE-PD

DOWNLOAD OUR NEWSLETTER

ACADEMY IN MADRID

ACADEMY IN CARDIFF

ACADEMY IN HEIDELBERG

FOLLOW US

IMPROVE-PD Follow

Identification and Management of Patients at Risk – Outcome and Vascular Events in Peritoneal Dialysis. An EU funded consortium of 22 organisations (GA 812699)

Retweet on Twitter IMPROVE-PD Retweeted

KDIGO @gokdigo ·

6 Feb

KDIGO invites you to share your feedback on the Scope of Work for the KDIGO Controversies Conference on Kidney Disease and Heart Failure. You can download the SOW and share comments via the feedback survey on the conference website through February 21: https://kdigo.co/Kidney-Disease-Heart-Failure-Controversies-Conference…

Reply on Twitter 1754922663976292706 Retweet on Twitter 1754922663976292706 15 Like on Twitter 1754922663976292706 53 Twitter 1754922663976292706

Retweet on Twitter IMPROVE-PD Retweeted

MarieSkłodowskaCurie @mscactions ·

8 Jan

Introducing our new financial guide, simplifying #MSCA project management!

✔️ Ideal for applicants, coordinators, managers
🚀 Covers Doctoral Networks, Fellowships, Staff Exchanges, COFUND programmes
📈 Clarifies recruitment, reporting, eligibility

Check it out below ⤵️

Reply on Twitter 1744282798507401578 Retweet on Twitter 1744282798507401578 76 Like on Twitter 1744282798507401578 173 Twitter 1744282798507401578

Retweet on Twitter IMPROVE-PD Retweeted

MarieSkłodowskaCurie @mscactions ·

7 Nov

Today marks the 156th anniversary of the extraordinary Marie Skłodowska-Curie! 🎂 Her legacy thrives through the #MSCA, empowering researchers worldwide.

Join the celebration and discover how you can contribute to the spirit of innovation she ignited. 👇

Reply on Twitter 1721802382776901982 Retweet on Twitter 1721802382776901982 141 Like on Twitter 1721802382776901982 440 Twitter 1721802382776901982

IMPROVE-PD @improvepd ·

25 Sep

Lessons from animal models: unraveling kidney fibrosis.
Read more here!:
Carnosinase-1 Knock-Out Reduces Kidney Fibrosis in Type-1 Diabetic Mice on High Fat Diet #mdpiantioxidants via @antioxidants_OA

Reply on Twitter 1706301350521286820 Retweet on Twitter 1706301350521286820 1 Like on Twitter 1706301350521286820 1 Twitter 1706301350521286820

FUNDING PROGRAMME

IMPROVE-PD is funded by the Horizon 2020 Framework Programme of the European Union through the Marie Skłodowska-Curie Programme as an Innovative Training Network (ITN-ETN).

The aim of this Programme is to train a new generation of creative, entrepreneurial and innovative early-stage researchers, able to face current and future challenges and to convert knowledge and ideas into products and services for economic and social benefit.

OUR EARLY STAGE RESEARCHERS

ESR1. Ivan_Damgov_ImprovePD_website_profile

Ivan Damgov

Ivan (Bulgarian), Biostatistician and SAS Certified Clinical Trials Programmer with Experience in Study Design and Statistical Analysis.
RESEARCH PROJECT: Longitudinal PD risk profiling and CV outcome analysis.
HOSTING ORGANISATION: Universitaets-Klinikum Heidelberg (Germany)

ESR2. Iva

Iva Marinovic

Iva (Croatian), MSc. Drug Research and Development.
RESEARCH PROJECT: Understanding and modulating the molecular basis of peritoneal solute transport to improve peritoneal dialysis efficacy and outcome.
HOSTING ORGANISATION: Universitaets-Klinikum Heidelberg (Germany)

ESR3. Obaida

Obaida Istanbuly

Obaida (Syrian), qualified medical doctor who has critical thinking in biostatistics and experience in working with clinical electronic databases and dissemination evidence-based medicine.
RESEARCH PROJECT: Inflammation and Cardiovascular Risk in Peritoneal Dialysis.
HOSTING ORGANISATION: Keele University (United Kingdom)
LINKEDIN

ESR4. Madonna Salib

Madonna Atef Boulos Salib

Madonna (Egyptian), Erasmus Mundus European Master’s degree in Quality in Analytical Laboratories. Guest Researcher at the National Institute of Standards and Technology, USA. Bachelor of Science in Pharmaceutical Sciences.
RESEARCH PROJECT: The determination of pertinent biomarkers, particularly those related to inflammation and fibrosis, to evaluate the risk of cardiovascular outcomes among end stage kidney disease patients undergoing chronic dialysis.
HOSTING ORGANISATION: INSERM Nancy Clinical Investigation Centre (France)
LINKEDIN

ESR5. EVA IMPROVE PD

Eva Arriero

Eva (Spanish), Biochemist (FU Berlin) with background in Mol. Biology, Biostatistics, Biophysics and languages. “It is simply less entropic to perform highest with yourself and your environment".
RESEARCH PROJECT: Evaluation of the epithelial to mesenchymal transition in peritoneal functional decline and cardiovascular disease.
HOSTING ORGANISATION: CBM-CSIC (Spain)

ESR6. VMarchant

Vanessa Marchant

Vanessa (Chilean), Bachelor of Science, Licentiate of Biochemistry, Biochemist, PhD candidate, Universidad Austral de Chile.
RESEARCH PROJECT: Humoral factors communicating peritoneal to systemic inflammation and cardiovascular disease.
HOSTING ORGANISATION: Universidad Autónoma de Madrid (Spain)
LINKEDIN

ESR7. Ines Costa

Inês Paula Dias Costa

Inês (Portuguese), PhD Student with a Master’s degree focused in Biochemistry from Universidade do Porto. Several years of research experience and skilled in immunology, molecular biology and genetics.
RESEARCH PROJECT: The Role of the peritoneal barrier in controlling the local-systemic inflammatory link.
HOSTING ORGANISATION: Université Catholique de Louvain (Belgium)
LINKEDIN

ESR8. Esra

Esra Cetin

Esra (Turkish). Master’s degree in Biology. Focusing on gaining the necessary knowledge and expertise in the immunology field to complete her Ph.D. studies.
RESEARCH PROJECT: Mechanisms and therapeutic prevention of cardiovascular disease development following peritonitis in peritoneal dialysis patients.
HOSTING ORGANISATION: Cardiff University (United Kingdom)
LINKEDIN

ESR9. Shrea

Shrea Roy

Shrea (Indian), Bachelor - Biotechnology Engineering (India), Masters - Molecular Life Sciences (Germany)
RESEARCH PROJECT: Hyaluronan (HA)-Regulation of Vascular Smooth Muscle Cell Phenotype and Vascular Classification in Peritoneal Dialysis.
HOSTING ORGANISATION: Cardiff University (United Kingdom)
LINKEDIN

ESR10. Jamie

Jamie Kane

Jamie (British), Biomedical Sciences at Manchester for BSc and carried on to a Biological Sciences MRes at Manchester.
RESEARCH PROJECT: The impact of local and systemic inflammation triggered by chronic kidney disease and peritoneal dialysis on the progression of uremic cardiomyopathy, vascular calcification, and atherosclerosis.
HOSTING ORGANISATION: Amsterdam UMC (The Netherlands)
LINKEDIN

ESR11. Robin Hoogenboom

Robin Hoogenboom

Robin Hoogenboom (Dutch) studied Biologie & medisch laboratoriumonderzoek and Master of science Infection and Immunity.
RESEARCH PROJECT: The Role of the Microbiome for Cardiovascular Risk and the Mode-of-Action of a Novel Dipeptide containing PD Fluid.
HOSTING ORGANISATION: Zytoprotec (Austria)
LINKEDIN

ESR12. Juan Manuel Sacnun

Juan Manuel Sacnun

Juan Manuel (Argentinean), Degree in Biotechnology at the Universidad Nacional de Rosario, Argentina.
RESEARCH PROJECT: From Mechanism to First-in-Human Application - Cardiovascular Effects of a Novel Kinase-Inhibitor-containing Cytoprotective PD Fluid.
HOSTING ORGANISATION: Zytoprotec (Austria)
LINKEDIN

ESR13. Valeria

Valeria Kopytina

Valeria (Russian), graduated in Chemistry from Voronezh State University in Russia and finished her Master’s degree in pharmacological research at the Universidad Autónoma de Madrid specialized in cardiovascular diseases.
RESEARCH PROJECT: Study of a novel peritoneal dialysis fluid based on Stevioside
HOSTING ORGANISATION: CBM-CSIC (Spain)
LINKEDIN

ESR14. Krystell

Krystell Oviedo

Krystell (Costa Rica), studied Medicine in the University of Costa Rica, and a Master in Palliative Oncology in Spain. Involved in the clinical practice in the Social Security System in Costa Rica, and also studied Oncology at the University of Nottingham. Professor for postgraduate studies in the University of Costa Rica.
RESEARCH PROJECT: Translation of research into development of a commercial peritoneal dialysis fluid.
HOSTING ORGANISATION: Baxter Healthcare (Austria)
LINKEDIN

ESR15. Michail Evgeniou

Michail Evgeniou

Mike (Greek) studied Biomedical Science at the Technological Institute of Athens and did his MSc. in Bioinformatics at the National and Kapodistrian University of Athens. He worked on the field of In sillico drug design as software developer and data analyst.
RESEARCH PROJECT: Using big data from the public domain for in-silico screening compounds with therapeutic potential in PD.
HOSTING ORGANISATION: Medical University of Vienna (Austria)
LINKEDIN

CONSORTIUM

The IMPROVE PD consortium connects leading academic and industrial researchers in this field internationally, who will cooperate in the shared goal of understanding the mechanisms of inflammation-driven cardiovascular disease in PD patients, developing individualized approaches to identify those at risk, and testing new therapies in them.

CONSORTIUM MEMBERS

COORDINATOR

Agencia Estatal Consejo Superior de Investigaciones Científicas (ES)

BENEFICIARIES	PARTNER ORGANISATIONS
Cardiff University (UK)	Dutch Kidney Foundation (NL)
Baxter Healthcare (AT)	The European Peritoneal Dialysis Association (UK)
INSERM Nancy Clinical Investigation Centre (FR)	Fresenius Medical Care (DE)
University of Keele (UK)	Kidney Research UK (UK)
Medical University of Vienna (AT)	Delta 4 (AT)
Université Catholique de Louvain (BE)	Servicio Madrileño de Salud- Instituto de Investigación del Hospital Universitario La Paz (ES)
Universitaets-Klinikum Heidelberg (DE)	University of Ghent (BE)
Amsterdam UMC (NL)	Renal Registry UK (UK)
Zytoprotec GmbH (AT)	Australia/New Zealand Renal Registry (AU)
Universidad Autónoma de Madrid (ES)	Poznan University of Medical Science (PL)
	Institut de Recerca Biomèdica de Lleida (ES)